Jean-Yves Tanguy

Jean-Yves Tanguy

Auto-generated profile, based on publicly available information

Jean-Yves Tanguy

Department of Radiology Centre Hospitalier Universitaire d'Angers Angers France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2010 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
CLCédric Lamirel
Cédric Lamirel
JCJulien Cassereau
Julien Cassereau
ICIsabelle Cochereau
Isabelle Cochereau
CVCatherine Vignal-Clermont
Catherine Vignal-Clermont
OPOlivier Pajot
Olivier Pajot
CVChristophe Verny
Christophe Verny
The authors report a case of one patient from a family carrying the homoplasmic Leber hereditary optic neuropathy (LHON) G11778A mitochondrial DNA mutation with papilloedema 9 months prior to the acute stage of LHON and still present at the onset of visual loss. During the vision loss, the MRI demonstrated a T2 hyperintensity and an enhancement of the prechiasmal left optic nerve, suggesting the existence of an inflammatory mechanism. A retrospective review of the chart of two others members of the same family, with bilateral optic disc oedema at onset of the vision loss, suggests that the relationship of papilloedema and acute phase of LHON may not be just a coincidence, at least in this family. The visual loss related to LHON could have been triggered in the setting of the chronic papilloedema, associated with the intracranial hypertension.

1 July 2010 in Journal of Clinical Neuroscience
Verified
Journal Article
Closed access
ACAnne Clavreul
Anne Clavreul
NPNicole Piard
Nicole Piard
JTJean-Yves Tanguy
Jean-Yves Tanguy
EGEric Gamelin
Eric Gamelin
MRMarie-Christine Rousselet
Marie-Christine Rousselet
PMPhilippe Menei
Philippe Menei

31 July 2024 in Neurocomputing
Verified
Journal Article
Open access
YMYueran Ma
Yueran Ma
JLJianxun Lou
Jianxun Lou
JTJean-Yves Tanguy
Jean-Yves Tanguy
PCPadraig Corcoran
Padraig Corcoran
HLHantao Liu
Hantao Liu

27 December 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AZAlban Ziegler
Alban Ziegler
ADAnne-Sophie Denommé-Pichon
Anne-Sophie Denommé-Pichon
SBSophie Boucher
Sophie Boucher
NBNathalie Bouzamondo
Nathalie Bouzamondo
ECEstelle Colin
Estelle Colin
DBDominique Bonneau
Dominique Bonneau

29 September 2026 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
AVAïna Venkatasamy
Aïna Venkatasamy
APAnne R. J. Péporté
Anne R. J. Péporté
RKRomain KANIA
Romain KANIA
JTJean‐Yves Tanguy
Jean‐Yves Tanguy
BGBenoît Gallix
Benoît Gallix
Objective: Increased MRI use for nonspecific symptoms has led to frequent detection of small or incidental vestibular schwannomas (VS), most of which never require treatment. This study aimed to develop and validate a stepwise model to stratify VS patients using early MRI findings and reduce unnecessary long‐term surveillance. Study Design: Retrospective multicenter cohort study with external validation. Setting: Three tertiary referral centers in France (Strasbourg, Angers) and Switzerland (Frauenfeld). Methods: Patients aged ≥18 years with sporadic VS and ≥3 consecutive MRIs before any intervention were included (2000‐2020). Prior treatment, intralabyrinthine schwannomas, or incomplete imaging led to exclusion. A training cohort (n = 156) and an independent validation cohort (n = 32) were analyzed. Logistic regression and random forest models were used to identify predictors of treatment. A clinically applicable stepwise algorithm integrating baseline tumor volume, annual growth rate, and symptom presence was developed. Results: The optimized model achieved 100% sensitivity in both cohorts, ensuring no patient requiring treatment was missed. Specificity was 74% in the training cohort and 48% in the validation cohort. After 1 follow‐up MRI, surveillance could be safely discontinued in half of the cohorts (respectively 74% and 48% of patients). Larger baseline tumor volume, symptom presence, and higher growth rate were significant predictors of treatment ( P < .05). Conclusion: A stratified, stepwise approach enables safe reduction of long‐term MRI surveillance in approximately half of VS patients, supporting personalized follow‐up and more efficient healthcare use.